Testing for Hereditary Predisposition in Patients with Gynecologic Cancers, Quo Vadis? - 29/05/16
, Kasmintan A. Schrader, MBBS, FRCPC, PhD c, dAbstract |
Genetic testing for a hereditary predisposition to gynecologic cancers has been available clinically since the 1990s. Since then, knowledge of the hereditary contribution to gynecologic cancers has dramatically increased, especially with respect to ovarian cancer. Although knowledge of the number of gynecologic cancer–predisposing genes has increased, the integration of genetic predisposition testing into routine clinical practice has been much slower. This article summarizes the technical and practical aspects of genetic testing in gynecologic cancers, the potential barriers to more widespread access and practice of genetic testing for hereditary predisposition to gynecologic cancers, and the potential solutions to these barriers.
Le texte complet de cet article est disponible en PDF.Keywords : Genetic predisposition, Gynecologic cancer, Multiplex genetic testing, Gene panels
Plan
| Disclosure Statement: AstraZeneca - Advisory Board member and cochair of industry-sponsored education meeting around BRCA testing in ovarian cancer (G. Mitchell); no disclosures (K.A. Schrader). |
Vol 9 - N° 2
P. 301-306 - juin 2016 Retour au numéro
Article précédent
- Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma
- Bojana Djordjevic, Russell R. Broaddus
- Prophylactic Gynecologic Specimens from Hereditary Cancer Carriers
- Patricia A. Shaw, Blaise A. Clarke
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?